Summary Carboxypeptidase G2, a zinc metalloenzyme isolated from Pseudomonas sp. strain which catalyses the hydrolytic cleavage of reduced and non-reduced folates to pteroates and L-glutamate, has been linked to a monoclonal antibody (W14A) raised to human chorionic gonadotrophin. The coupling efficiency and retention of antibody and enzymatic activities are compared for three separate methods of preparing 1:1 conjugates. Preliminary in vitro studies on the cytotoxicity of the free enzyme and the conjugated enzyme towards JAR choriocarcinoma cells are reported. Despite the limitations of the in vitro model, it could be demonstrated that a significant proportion of 106 choriocarcinoma cells lost viability when exposed to either free or conjugated enzyme for 72 hours at concentrations of carboxypeptidase G2 of 1-3 units ml-' of medium.
catalyses the hydrolytic cleavage of reduced and non-reduced folates to pteroates and L-glutamate, has been linked to a monoclonal antibody (W14A) raised to human chorionic gonadotrophin. The coupling efficiency and retention of antibody and enzymatic activities are compared for three separate methods of preparing 1:1 conjugates. Preliminary in vitro studies on the cytotoxicity of the free enzyme and the conjugated enzyme towards JAR choriocarcinoma cells are reported. Despite the limitations of the in vitro model, it could be demonstrated that a significant proportion of 106 choriocarcinoma cells lost viability when exposed to either free or conjugated enzyme for 72 hours at concentrations of carboxypeptidase G2 of 1-3 units ml- ' (Steinberg et al., 1983 rat is markedly inhibited by folate deficiency (Rosen et al., 1962 ).
An enzyme, carboxypeptidase G1, which catalyses the hydrolytic cleavage of reduced and non-reduced folates to pteroates and L-glutamate, was demonstrated to inhibit the growth of L1210 leukaemic cells, amongst others, in vitro . Both methotrexate-sensitive and methotrexate-resistant cell lines were similarly affected and this encouraged us to consider the choriocarcinoma model where methotrexate resistance may result from amplification of dihydrofolate reductase activity, as in a number of other malignancies (Dedhar et al., 1983) . Antibodydirected enzymatic deprivation of folate might be a valuable adjunct to conventional chemotherapy.
Carboxypeptidase G2 (Sherwood et al., 1985) (Searle et al., 1981) and radioimmunolocalisation studies in patients (Goldenberg et al., 1981; Begent et al., 1985) have already indicated that there is some selective retention of these antibodies in the locality of hCG-producing tumours. Autoradiography with iodine (125I)-labelled antibodies suggests the major proportion remains extracellular in the xenograft model (Sharma, 1983) . The preparation of anti-hCG-carboxypeptidase G2 conjugates has been undertaken to establish suitable methods to link the proteins without unacceptable losses of antibody or enzyme activity. Preliminary in vitro studies with JAR choriocarcinoma cells have been initiated in order to gain some insight into the requirements of local concentration, time of retention, and enzymatic activity required to produce a cytotoxic effect. Three methods were used in this study to couple carboxypeptidase G2 to anti-human chorionic gonadotrophin antibody. All were based on heterofunctional reagents which react with an amino group on one protein and a thiol residue on the second. A variety of coupling methods was chosen to enable the in vivo stability of the different bonds to be studied.
Carboxypeptidase G2 does not possess any free thiol groups (Minton et al., 1984) and was not considered suitable for the introduction of such residues because of loss of activity under the reaction conditions used for the reduction of 2-pyridyldisulphide groups. This limitation did not apply to the antibody, and hence it was this molecule which was thiolated. The reaction of the heterobifunctional reagents with amino groups occurs at approximately neutral pH and caused no major difficulties with the enzyme.
The heterobifunctional reagents used were Nsuccinimidyl-3-(2-pyridyldithio)-propionate (SPDP) which generates a disulphide bridge between the two protein molecules; the N-hydroxysuccinimide ester of iodoacetic acid (NHIA) which forms a thioether bond between the protein molecules and N-maleimidobenzoyl succinimide ester (MBS), the active maleimide bond of which forms a thioether bond with a thiol group on one protein, with the active ester acylating an amino group on the second protein.
Materials and methods

Materials
Chemicals N-Succinimidyl-3-(2-pyridyldithio) propionate (SPDP) was purchased from Pharmacia Ltd., Milton Keynes, UK; N-hydroxysuccinimide and N,N-dicyclohexylcarbodiimide were purchased from Aldrich Ltd., Gillingham, Dorset, UK; Nmaleimidobenzoyl succinimide ester (MBS) and 5, 5'-dithiobis-(2-nitrobenzoic acid) (DTNB) were purchased from Sigma Ltd, Poole, Dorset, UK; 1,4-dioxan (which was applied to a column of aluminium oxide before use), iodoacetic acid and all other chemicals, which were of 'Analar' grade, were purchased from B.D.H. Ltd., Poole, Dorset, UK.
Biological materials
Carboxypeptidase G2 (330 U mg-1) was produced by the Microbial Technology Laboratory following a previously described protocol (Sherwood et al., 1985) . Antihuman chorionic gonadotrophin, anti-hCG W14A, an IgG1 mouse monoclonal antibody was prepared from ascites as reported previously (Searle et al., 1984 
Methods
Determination of biological activities Carboxypeptidase G2 activity was measured spectrophotometrically at 37°C in tris-HCl buffer with 0.06mM methotrexate as substrate in a total volume of 1 ml. The reaction was started by the addition of enzyme and followed by the decrease in absorbance at 320 nm (Hughes et al., 1982; McCullough et al., 1971 ).
Anti-hCG activity relative to starting material was measured as described previously (Searle et al., 1984) . Antiserum dilution curves were set up as follows: each tube contained a mixture of phosphate buffer (200 Ml), antibody or conjugate at different dilutions in 1/400 normal mouse serum in phosphate buffer (50pl), Il25-hCG (50p1 of stock solution specific activity 180 MCi pg-diluted to achieve 60-70,000 c.p.m.). Reaction mixtures were incubated for 16 h at room temperature and then rabbit antimouse immunoglobulin (50 1l) added to a final dilution of 1/280 together with 10% polyethylene glycol 6000 (50 1I). The whole was incubated for a further 2 h at room temperature and then filtered and counted (Searle et al., 1984) .
Thiolation of anti-hCG One hundred pl of a stock solution of SPDP reagent (2.08mg ml-1) in ethanol were added, with stirring, to a solution of anti-hCG (1O mg) in phosphate buffer (3.5 ml). After stirring at room temperature for 30 min, the mixture was applied to a column of BioGel P30 (15mm x 240mm) pre-equilibrated with acetate buffer and eluted with the same buffer. Immunoglobulin-containing fractions were tested (Carlsson et al., 1978) to determine the degree of incorporation of 2-pyridyldisulphide residues.
Dithiothreitol (3.9 mg) was added to the substituted immunoglobulin solution (5.1 ml). After stirring for 20 min at room temperature, the mixture was applied to a column of BioGel P30 (15mm x 240 mm) pre-equilibrated with phosphate buffer, and eluted (1.75 ml fractions) with the same buffer. Fractions containing anti-hCG (7 ml) were pooled.
Preparation of anti-hCG-carboxypeptidase G2 conjugate using NHIA One hundred and twentythree pl of a stock solution of NHIA (12.5mg ml 1) (Rector et al., 1978) in dimethylformamide were added with stirring, in portions, to a solution of carboxypeptidase G2 (11 mg) in phosphate buffer (2.5nml). After stirring for 40min at room temperature, the mixture was applied to a column of Bio-Rad P30 (15mmx240mm), pre-equilibrated with phosphate buffer, and eluted (1.75 ml fractions) with the same buffer. The carboxypeptidase G2 fraction (7 ml) was tested spectrophotometrically to confirm the introduction of iodoacetyl groups (Thorpe et al., 1984) .
The iodoacetylated carboxypeptidase G2 was mixed with thiolated anti-hCG prepared as above, and the mixture concentrated to 2.5ml by ultrafiltration and allowed to react for 60 h at room temperature.
Anti-hCG-carboxypeptidase G2 conjugate was purified by column chromatography on Sephacryl S300 Superfine (26mm x 650mm), pre-equilibrated and eluted with phosphate buffer. Fractions (2.75ml) containing antibody and enzyme activity were pooled from several preparations to give a total of 160ml, concentrated 10-fold by ultrafiltration and stored at -70°C.
Preparation of anti-hCG-carboxypeptidase G2 comjugate using SPDP Fifty ul of a stock solution of SPDP reagent (2.1 mgml-1) in ethanol were added with stirring, to a solution of carboxypeptidase G2 (5.5mg) in phosphate buffer (2.4ml). After stirring for 40min at room temperature, the mixture was applied to a Sephadex G25M (PD1O) column, pre-equilibrated and eluted with phosphate buffer. An aliquot was retained for the determination of 2-pyridyldisulphide residueincorporation as before. Fractions (0.5 ml) were collected and assayed for enzyme activity. The peak fractions (3.5ml) were mixed with thiolated antihCG (5mg, 3.5 ml), the mixture concentrated to 2.5ml by ultrafiltration, and allowed to react for 60 h at 4°C. Anti-hCG-carboxypeptidase G2 conjugate was purified by chromatography on a column of Ultrogel AcA34 (22mmx900mm), preequilibrated and eluted with phosphate buffer. Fractions (2 ml) were collected and assayed as before.
Preparation of anti-hCG-carboxypeptidase G2 conjugate using MBS Fifty pl of a stock solution of MBS (4.2mg ml-1 in tetrahydrofuran) were added with stirring to a solution of carboxypeptidase G2 (5.5mg) in phosphate buffer (2.4ml). After stirring for 40min, the mixture was applied to a Sephadex G25M (PD10) column pre-equilibrated and eluted with phosphate buffer. Fractions (0.5ml) were collected and assayed for enzyme activity. Peak fractions (3.5ml) were pooled and an aliquot retained for the determination of MBS incorporation by measuring the decrease of the thiol content on its addition to mercaptoethanol (100nmol) using Ellman's reagent (DTNB) (Sedlack & Lindsay, 1968) . The pooled, activated enzyme was mixed with thiolated anti-hCG, (5mg, 3.5ml) the mixture concentrated to 2.5ml by ultrafiltration and allowed to react for 60h at 4°C. Anti-hCGcarboxypeptidase G2 was isolated by chromatography on a column of Ultrogel AcA 34 (22mmx900mm) pre-equilibrated and eluted with PBS. Fractions (2ml) were collected and assayed as before.
Growth inhibition of JAR choriocarcinoma cells by carboxypeptidase G2 Cells were trypsinized (0.5% trypsin and 0.02% EDTA in saline) from stock flasks and seeded at 1 x 105 cells/well in 1 ml DMEM +10% foetal calf serum per well for controls and 1ml 199+10% foetal calf serum for folate-depleted controls. After 24h, viable cells in triplicate wells were estimated by trypsinization of the adherent cells and counting with a haemocytometer using trypan blue uptake. The stock media were renewed at 24 h intervals in further control wells for 4 days, while experimental triplicate wells were exposed to medium 199 containing 1.5, 3.0 and 15.0 units of carboxypeptidase G2 ml-1 respectively, these media also being renewed at 24 h intervals. (Table III) . For one antihCG-carboxypeptidase G2 conjugate (NHIAlinked), a measurable effect was detected at -1 unit of enzyme 10-5 cells in medium 199+10% foetal calf serum (Table III) . Comparable results were obtained by maintaining the cells in unchanged medium over 72 h and adding small volumes of concentrated enzyme daily. 
Discussion
In order for the conjugate between anti-hCG (W14A) and carboxypeptidase G2 to function as a potential anti-neoplastic agent, it must express both immunological and enzymatic activity. The newlycreated linkage must not be susceptible to speedier cleavage in vivo than the general metabolic breakdown to which the proteins themselves would be exposed prior to reaching the tumour cell. The properties of cross-linking agents have been reviewed extensively (Means & Feeney, 1971; Weetall & Cooney, 1981; Ghose et al., 1983; Han, 1984) in relation to the sites of modification of the proteins. One of the most common approaches to conjugate preparation has been to enrich one component with thiol groups. Many antibody conjugates, particularly immunotoxins, have been coupled using a direct disulphide bridge but opinions differ as to the stability of this linkage in vivo. For example, it has been concluded from experiments on the immunosuppressive activity of abrin conjugates in mice (Thorpe et al., 1982) that the disulphide bond, when used to couple two unrelated proteins, is not reinforced by covalent forces and may be particularly susceptible to cleavage in vivo. Similarly, instability of a disulphide-linked conjugate between anti-transferrin antibody and ricin A chain may have been encountered in mice (Trowbridge et al., 1981) . In contrast, data have been presented on the depletion of 6 neoplastic BCL cells in mice, with a ricin A disulphide-linked antibody, which suggests requisite stability is maintained in this system (Vitetta et al., 1982) . It is difficult to predict the in vivo stability of conjugates with different protein components. Both disulphide-bridged and thio-ether-linked conjugates of anti-hCG and carboxypeptidase G2 have been prepared and all three coupling methods tested produced satisfactory conjugates in that antibody and enzyme activities were retained. Their in vivo stabilities are currently under investigation.
The studies with JAR cells reported here suggest that carboxypeptidase G2, even when conjugated to anti-hCG antibody, is cytotoxic to choriocarcinoma cells. Actual levels of administered enzyme needed to destroy the cells can vary in different cell lines (for example, 30 units 10-5 BeWo choriocarcinoma cells) and are much higher than were anticipated by analogy with earlier work . The enzyme remains active in the medium as estimated by spectrophotometric assays of diluted medium in buffer, but this does not eliminate rigorously the possibility of some inhibition of enzyme in the cell medium. In dealing with an antibody to a secreted antigen such as human chorionic gonadotrophin, the saturation of antibody sites at the cell surface need not be a limiting factor, since accumulation in vivo would depend rather on the concentration gradient of soluble antigen. Extrapolation to the in vivo model depends upon too many variables to be certain of an in vivo response from these measurements. However, the in vitro model can be used to answer specific questions. For example, further work is necessary to see how far cells which have been exposed to the enzyme can be rescued by withdrawing the enzyme and administering folate, since this would simulate more correctly the potential situation in vivo. It is premature to draw conclusions about the relative potency of the enzyme and its conjugate from these results. The model may be complicated by the release of folate from damaged cells into the medium. Provided the folate remains in its intracellular pentaglutamate form, it will be unlikely to re-enter viable cells through monoglutamate transport pathways. However, competition may develop between the released pentaglutamate and monoglutamate substrate in the medium such that, at low levels of the enzyme, dose responses in the presence of dying cells will be difficult to interpret rigorously. So far the efficacy of the enzyme has been demonstrable over a rather narrow range of cell numbers, in the plates used, which had to be balanced against the relatively short time before the cells reached confluence: it is possible that the cell doubling time and the number of damaged cells releasing folate are critical experimental parameters to demonstrate the growth inhibition. So far it has not been possible for us to remove the dependence of the cells on 10% foetal calf serum in these media and the model may be complicated by potential interactions of folate with folate-binding protein in the serum. It had been hoped that the cells could be induced to grow satisfactorily in medium 199 with known levels of folate added, to study the effect of the enzyme more extensively. Despite the limitations of the model the inhibition of the cell growth by carboxypeptidase G2 in the free and conjugated form is significant and consistent with the postulate that the inhibition is due to folate depletion. A significant proportion of the cells appear to lose viability at concentrations of enzyme as low as 3Uml-1. Preliminary data (not shown) on the uptake of tritiated thymidine or tritiated leucine by JAR cells exposed to carboxypeptidase G2 are in general accordance with these results but remain to be evaluated fully. The incorporation of both thymidine and leucine can theoretically be distorted by folate depletion (Taheri et al., 1981; Grzelakowska-Sztabert, 1983) and are therefore unsatisfactory direct measures of cell viability in this model.
How far are the in vitro observations an indication of the potential of the anti-hCGcarboxypeptidase G2 conjugates for destroying choriocarcinoma cells in vivo? Normal serum folates in the human consist of a fairly constant level of 10-formyl-tetrahydrofolate maintained by homeostatic mechanisms and variable levels of 5-methyl-tetrahydrofolate as a storage form (Halpern et al., 1977) . In attempts to deplete folate artificially there will be little help from normal catabolism. The total folate requirement of a 70kg subject is maintained by an intake of only 50 pg daily (Halpern et al., 1977) . In conditions where the total folate pool is depleted, as in some malignancies, there is a shift whereby 10-formyl-folates are preferentially formed from folic acid. In some adult leukaemic patients there are increased levels of 10-formyl-tetrahydrofolate, although both total folate and 5-methyl-tetrahydrofolate levels are significantly decreased.
Carboxypeptidase G2, in the locality of the tumour, will have to encounter a background level of interstitial folate and the serum folate pool with which the interstitial fluid is in equilibrium. From figures for serum folate levels in normal and leukaemic subjects (Ratanasthian et al., 1974) , a reasonable estimate for total serum folates would be I0 ng ml-1, presumably in equilibrium with interstitial content. Serum folate levels should, however, be considerably reduced through the activity of circulating enzyme-antibody conjugate during treatment. Had we been able to demonstrate JAR cell cytotoxicity in DMEM +10% foetal calf serum (i.e. 4,000 ng ml -1 folate) we would be confident that the enzyme is sufficiently potent to attack small residual deposits of choriocarcinoma cells in vivo as a conjugated single agent. The 199 medium + 10% foetal calf serum (1 Ing ml-folate) is closer to the estimated serum background level, but to maintain a concentration of 15Uml-1 of enzyme in the locality of the tumour in vivo could present difficulties. A great deal will depend on the distribution and stability of the enzyme conjugate in vivo which is the subject of current investigations.
